<DOC>
	<DOC>NCT00429260</DOC>
	<brief_summary>The primary objective is to evaluate the safety and tolerability of abrupt discontinuation of saredutant over 1 week in outpatients with depression who completed 8 weeks of treatment with saredutant 100 mg once daily. The secondary objective is to evaluate the safety and tolerability of 8 weeks of open-label treatment with saredutant 100 mg once daily in outpatients with depression.</brief_summary>
	<brief_title>A Study Evaluating the Safety and Tolerability of Abrupt Discontinuation of Saredutant in Patients With Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<criteria>Diagnosis of major depressive disorder,single or recurrent episode, as defined by Diagnostic and Statistical Manual of Mental Disorders DSMIV criteria Total score of &lt;22 on the MontgomeryAsberg Depression Rating Scale (MADRS). Duration of the current depressive episode is less than 1 month or greater than 2 years. Total score of &lt;25 on the Mini Mental State Examination (elderly patients â‰¥65 years only). Patients with a history or presence of bipolar disorders or psychotic disorders. Patients with alcohol dependence or abuse or substance dependence or abuse in the past 6 months except nicotine or caffeine dependence. Patients who have used the following prior to entry: benzodiazepines or sedativehypnotics more than 2 days per week within 1 month, antipsychotics within 1 month, fluoxetine within 1 month, monoamine oxidase inhibitors within 2 weeks, other antidepressants, anxiolytics, or moodstabilizer (lithium, anticonvulsants) within 1 week. The investigator will evaluate whether there are other reasons why a patient may not participate.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>depression</keyword>
	<keyword>antidepressive agents</keyword>
</DOC>